Humoral immune response against SARS-CoV-2 and polyethylene glycol elicited by anti-SARS-CoV-2 mRNA vaccine, and effect of pre-existing anti-polyethylene glycol antibody in patients with hematological and autoimmune diseasesResearch Article Published on 2024-05-172024-09-05 Journal: Heliyon [Category] update2024, [키워드] Anti-CD20 antibody Anti-polyethylene glycol antibody Autoimmune disease COVID-19 hematological disease mRNA vaccine [DOI] 10.1016/j.heliyon.2024.e31489 PMC 바로가기 [Article Type] Research Article
Infections associated with bendamustine and anti-CD20 antibody in untreated follicular lymphoma: a real-world studyShort Communication Published on 2023-07-282024-09-04 Journal: Journal of clinical and experimental hematopathology : JCEH [Category] 대상포진, [키워드] Anti-CD20 antibody Bendamustine cytomegalovirus Follicular lymphoma Infection [DOI] 10.3960/jslrt.23015 PMC 바로가기 [Article Type] Short Communication
Optimal time for COVID-19 vaccination in rituximab-treated dermatologic patientsImmunology Published on 2023-03-152024-09-05 Journal: Frontiers in immunology [Category] update2024, [키워드] Anti-CD20 antibody Autoimmune diseases COVID-19 vaccines immune-mediated dermatologic diseases immunogenicity rituximab Vaccines [DOI] 10.3389/fimmu.2023.1138765 PMC 바로가기 [Article Type] Immunology
Comparative analysis of humoral responses to BNT162b2 vaccine among patients with hematologic disorders and organ transplant recipientsArticle Published on 2022-12-012023-07-10 Journal: Transplant immunology [Category] COVID19(2023년), [키워드] Anti-CD20 antibody COVID-19 Hematopoietic transplantation Kidney transplantation vaccination [DOI] 10.1016/j.trim.2022.101713 PMC 바로가기
Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies림프성 악성종양 환자에서 BNT162b2 mRNA 백신 2회 및 3회 투여 후 항-SARS-CoV-2 항체 반응Article Published on 2022-06-012022-09-11 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] affected anti-CD20 Anti-CD20 antibodies Anti-CD20 antibody anti-CD38 anti-RBD Anti-RBD IgG antibody antibody concentration Antibody concentrations Antibody Response B-cell malignancies B-cell malignancy benefit binding domain booster Cell Cohort Concentration conducted Course COVID-19 COVID-19 patient COVID-19 patients disorders dose effective evaluate haematological malignancies haematological malignancy Haematologicalmalignancies humoral Humoral response humoral responses IgG Immunocompromised increment IQR lymphoid lymphomas malignancies malignancy median monoclonal Mortality mRNA vaccination mRNA vaccine of BNT162b2 Patient patients patients treated plasma Plasma cell Prophylaxis quantification RBD SARS-CoV-2 Seroconversion seroconversion rate seroconverted serological serological response serology significantly spike the disease the vaccine therapy third dose Vaccine vaccine dose [DOI] 10.1016/j.cmi.2022.02.029 PMC 바로가기 [Article Type] Article
Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis다발성 경화증 환자의 항-COVID19 백신 접종에 대한 항체 매개 반응에 대한 질병 조절 치료의 효과Article Published on 2022-06-012022-09-11 Journal: Journal of Neurology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] Adverse adverse event adverse events age aligned analysed anti-CD20 Anti-CD20 antibodies Anti-CD20 antibody anti-CD20 treatment Anti-spike antibody Antibody Response CD19 CD19+ CD20 CD20 deplething therapies cell count cell-mediated immune cell-mediated immune response Cohort correlated COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccines depleting detectable diagnosed Disease-modifying therapies Effect elicited event female fingolimod Follow-up Frequency IgG antibody immune response investigation material median median age Multiple multiple sclerosis non-responders Patient proportion protective immune response Protein receiving recorded Responder responders symptomatic therapy titre treated Treatment vaccination Vaccine was reduced [DOI] 10.1007/s00415-022-11003-3 PMC 바로가기 [Article Type] Article
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies항암치료를 받는 환자의 코로나19 백신접종에 대한 항체 및 T세포 반응Article Published on 2022-06-012022-09-11 Journal: Journal for immunotherapy of cancer [Category] COVID19(2023년), MERS, SARS, 바이오마커, 변종, 진단, 치료기술, 치료제, [키워드] active treatment adrenal crisis Adrenal insufficiency Affect Anti-CD20 antibodies Anti-CD20 antibody Anti-viral antibodies antibody antibody formation Antibody titer Antibody titers Anticancer therapy B cells B-cell B.1.617.2 blockade Cancer CD4 CD8 Cell cellular Chemoimmunotherapy Chemotherapy Corticosteroids COVID-19 COVID-19 infection COVID-19 infections COVID-19 vaccination COVID-19 vaccinations COVID-19 vaccine trials cross-reactive cytokine detectable develop dose doses effector cells Endocrine expressed follicular generate healthy donor healthy donors helper cells Humoral response hypoadrenalism Hypothesis IgG antibody titer immune Immunocompromised immunogenic immunogenicity immunogenicity, vaccine Immunotherapy intracellular cytokine staining Lymphocytes mRNA vaccine Multiple myeloma Myeloma n=36 no differences oncology patients Participants Patient Patients with cancer PD-1 peptide peptides Phase 3 profile Prophylactic RBD reactivity receiving Receptor binding domain Safe seronegative seronegative patient Side effect solid tumors spike Spike protein steroid Steroids Stress symptomatic T cell T cell response T cell responses T cells T follicular helper cells T-lymphocytes targeted therapy the SARS-CoV-2 therapy Treatment treatment groups tumors Two patient two patients vaccination Vaccinations Vaccine variant spike was measured were assessed were excluded wild-type WT spike [DOI] 10.1136/jitc-2022-004766 PMC 바로가기 [Article Type] Article
Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 VaccinationSARS-CoV-2 예방접종 후 혈액암 환자의 혈청전환율에 대한 치료의 영향Meta-Analysis Published on 2022-04-052022-09-12 Journal: The oncologist [Category] COVID19(2023년), SARS, 진단, [키워드] 95% confidence interval acute respiratory syndrome Anti-CD20 antibody antibody ARMS article chronic CLL CLL patient conducted Control coronavirus COVID-19 database determinants Efficacy first dose group healthy control hematologic Hematologic malignancy hematological Hematological malignancies Hematological malignancy Impact kinase literature review malignancies Meta-analysis organization Patient patient population patients treated Rate remained review risk SARS-CoV-2 SARS-CoV-2 vaccination SARS-CoV-2 vaccine second dose seroconversion rate significant difference significantly lower subject subjects the antibody response treated vaccination Vaccine [DOI] 10.1093/oncolo/oyac032 PMC 바로가기 [Article Type] Meta-Analysis
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination표준 2회 접종에 실패한 CLL 환자에서 3차 BNT162b2 mRNA COVID-19 백신 접종의 효능Clinical Trial Published on 2022-02-032022-09-12 Journal: Blood [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% CI acute respiratory syndrome administration Analysis anti-CD20 Anti-CD20 antibody anti-CD20 therapy antibody Antibody Response antibody response rate BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 mRNA vaccine BTK CLL coronavirus coronavirus disease COVID-19 COVID-19 vaccine dose evaluated humoral immunoglobulin A independent variable inhibitor lack leukemia lymphoma Patient regimen Registered response rate SARS-CoV-2 serum the antibody response therapy treated treated patient Treatment treatment-naïve patient Trial tyrosine vaccination Vaccine venetoclax were measured [DOI] 10.1182/blood.2021014085 PMC 바로가기 [Article Type] Clinical Trial
T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignanciesmRNA SARS-CoV-2 백신 후 T 세포 면역 반응은 림프 악성 종양 환자에서 혈청 전환이 없는 경우에도 자주 감지됩니다Clinical Trial Published on 2022-02-012022-09-12 Journal: British Journal of Haematology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] absence affected age and sex Analysis anti-cancer treatment anti-CD20 Anti-CD20 antibodies Anti-CD20 antibody anti-CD20 treatment antibody B-cell lymphoma cellular Chemotherapy treatment Complete conducted COVID-19 Diagnosis evaluated healthy subject Humoral response immune immune response Immunoglobulin increased mortality independent predictor lowest lymphoid lymphoid malignancies. lymphoma maintain malignancies malignancy Measures mRNA mRNA vaccination Multiple myeloma Patient Prospective Study Protective raise receiving Result SARS-CoV-2 vaccine Seroconversion seroconversion rate serological serological response seronegative patient subgroup of patient T-cell T-cell immune response T-cell Response Treatment vaccination [DOI] 10.1111/bjh.17877 PMC 바로가기 [Article Type] Clinical Trial